BenevolentAI IPO
BenevolentAI uses artificial intelligence to accelerate drug discovery and development, analyzing biomedical data to identify new therapeutic targets and drug candidates. The company has partnerships with pharmaceutical companies and has advanced multiple drug programs into clinical trials. Investors are interested in its AI-driven approach to addressing the high costs and long timelines of drug development.
What We Know
BenevolentAI went public on the London Stock Exchange in April 2022 through a merger with Odyssey Acquisition, a special purpose acquisition company. The transaction valued the company at approximately $1.5 billion. Since going public under the ticker BAI, the stock has experienced significant volatility, reflecting broader market challenges for AI and biotech companies. The company has continued to advance its drug discovery platform and clinical pipeline while operating as a public company, though it has faced the typical challenges of a growth-stage biotech firm in public markets.
Frequently Asked Questions
Has BenevolentAI had an IPO?
Yes, BenevolentAI completed its IPO in April 2022 on the London Stock Exchange through a SPAC merger. The company trades under the ticker BAI.
When is the BenevolentAI IPO date?
BenevolentAI already completed its IPO in April 2022. The company went public on the London Stock Exchange through a merger with Odyssey Acquisition.
How can I buy BenevolentAI stock?
You can buy BenevolentAI stock on the London Stock Exchange under the ticker symbol BAI. The stock is available through brokers that offer access to LSE-listed securities.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts